The comprehensive in silico analysis encompassed ADME and ProTox‐3.0 predictions for pharmacokinetic and safety profiles, followed by molecular docking simulations to assess binding affinities and interactions with four key AD targets: the sortilin receptor, clusterin receptor, Aβ peptide, and tau protein. This evidence concerns the gene MAPT and Alzheimer disease.